Feb 28, 2008 by Brian LawlerViroPharma in CheckSales of its antibiotic are slowing down, but there is a promising drug in its pipeline.
Feb 28, 2008 by Brian LawlerToo Much Hope in Human Genome SharesHuman Genome announces its guidance for 2008.
Feb 28, 2008 by Brian LawlerThird Wave Making Tiny RipplesThe small biotech could be poised for big returns.
Feb 25, 2008 by Brian LawlerA Positive Surprise for GenentechIts lead drug gets a conditional OK to treat breast cancer.
Feb 25, 2008 by Brian LawlerThe Most Interesting FDA Review for 2008Eli Lilly preps for an upcoming FDA review of its top pipeline drug.
Feb 25, 2008 by Brian LawlerSupplements Take a HitThe leaders of a top nutraceuticals producer are convicted.
Feb 22, 2008 by Brian LawlerThe Hypertension Fight ExpandsGilead and Glaxo win E.U. approval for a drug, and Encysive's sellout came just in time.
Feb 22, 2008 by Brian LawlerWhy Exelixis Might Be Out of ReachWith its shares in the dumps, is Exelixis going to be acquired?
Feb 21, 2008 by Brian LawlerA Bit of Irony From the FDAThe agency has a mixed message on drug importation.
Feb 20, 2008 by Brian LawlerResources for Rx StocksFor the latest in-depth news on your favorite biotech company, look here. And here.
Feb 15, 2008 by Brian LawlerDendreon's Not-So-New DataWe've heard it before, and it's just not that crucial.
Feb 14, 2008 by Brian LawlerSanofi StagnatesIts top drugs get some protection, but free cash flow drops.
Feb 14, 2008 by Brian LawlerWaking Cephalon UpCephalon presents its 2007 financial results and 2008 guidance.
Feb 12, 2008 by Brian LawlerA Pre-Emptive Strike on the FDAAdolor will likely be waiting an extra three months for a decision on Entereg.
Feb 8, 2008 by Brian LawlerHold on to GlaxoSmithKlineThis might be a tough year for the company, but its pipeline makes it a keeper.
